Skip to main content
Premium Trial:

Request an Annual Quote

UK Cancer Institute Buys TTP LabTech's Microplate Cytometer

NEW YORK (GenomeWeb News) – TTP LabTech has sold a microplate cytometer to Cancer Research UK for an RNAi-based whole-genome screening program aimed at identifying cytotoxic survival regulators.
 
Cancer Research UK’s London Research Institute will use the Acumen eX3 cytometer at a new high-throughput screening facility that will provide researchers with access to genome-wide siRNA and RNAi screening technologies. TTP said the Acumen X3 can help to speed genome screening time, and that it can read a 384-well plate in less than ten minutes.
 
The research techniques at the LRI are used in a broad range of research areas, “from yeast to flies to human cells,” the company said. The institute’s research includes studies of signaling processes that can control the intrinsic properties of cancer cells and their interactions with hosts as well as how the genome holds its integrity through environmental and endogenous changes.
 
Financial terms of the agreement were not released.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.